# CJC-1295 detection anti-doping status — WADA S2 and the FDA Record > CJC-1295 detection anti-doping: prohibited at all times under WADA Section S2, identified by LC-MS/MS, and not recommended for the FDA 503A bulks list at the 2024 PCAC. Prohibited at all times in sport under WADA Section S2, well-detected by modern assays, and reviewed but not recommended for the FDA 503A compounding bulks list. The status, stated first. ## WADA prohibited status: Section S2, all times The CJC-1295 detection anti-doping picture starts with one hard line: CJC-1295 is prohibited at all times — in and out of competition — under Section S2 of the WADA Prohibited List, which bans growth-hormone-releasing factors and their analogs along with peptide hormones, growth factors, and related substances. It is also banned by bodies such as the NCAA. As a long-acting GHRH analog, CJC-1295 falls squarely inside the S2 category, and out-of-competition use offers no exemption from it. The DAC variant's multi-day half-life is directly relevant to anti-doping exposure: with an estimated 5.8-to-8.1-day half-life and IGF-1 elevation persisting up to 28 days after multiple doses, the window during which the GH/IGF-1 axis is measurably altered is long [1]. The [WADA prohibited status](/detection-anti-doping) is a status fact, not a risk estimate — for tested athletes the substance is simply prohibited. ## Detection: LC-MS/MS and immunoassay identification CJC-1295 is well-detected. High-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to positively identify CJC-1295 as the active ingredient in an unknown "GHRH" pharmaceutical preparation seized in an anti-doping context — a definitive structural identification of the peptide [6]. The same analytical approaches that confirmed the compound in a seized product underpin its detection in anti-doping testing. Beyond direct mass-spectrometric identification of the peptide, the analog's biological footprint is also characterized. A human proteomic study found reproducible serum-protein changes after CJC-1295 administration that tracked with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5]. Detection assays for this class — LC-MS/MS and immuno-PCR among them — are well established, and the GH-releasing-factor category is an active target in sports drug testing. The DAC variant's pharmacokinetics widen the detection window further. Because a single dose elevates GH for six days or more and IGF-1 for nine to eleven days [1], the downstream biomarker signal persists long after the administration event — and after multiple doses IGF-1 stayed above baseline for up to 28 days [1]. A long-acting analog is, paradoxically, a long-detectable one: the same albumin tether that extends its action extends the period over which both the parent peptide and its IGF-1 footprint can be sampled. ## FDA status and the 2024 Pharmacy Compounding Advisory Committee CJC-1295 is not approved by the FDA, or any major regulator, for human use; it is handled and sold as a research chemical. It has no approved indication and no FDA-labeled dose. In 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed growth-hormone secretagogues including CJC-1295 as candidates for the 503A compounding bulks list — the category that governs which substances pharmacies may compound. FDA briefing materials cited immunogenicity and other safety concerns, and the committee did not recommend CJC-1295 for the 503A bulks list [10]. The practical effect is that CJC-1295 is not a compounding-eligible substance and remains outside the approved-drug and compounding-pharmacy systems alike. This distinction is worth stating precisely, because it is often blurred. Being reviewed by the PCAC is not the same as being approved, and being absent from the 503A bulks list is not a pending reclassification — it is the current determination. CJC-1295 has never held marketing approval, and the 2024 review left it where it was: an unapproved substance that pharmacies are not cleared to compound. ## The discontinued clinical program The long-acting DAC variant did once enter formal clinical development. ConjuChem's CJC-1295 (DAC) was studied in a Phase 2 trial in HIV-associated visceral obesity (NCT00267527) [7]. The program was discontinued, and the long-acting DAC analog did not advance toward approval. A patient death during the development era is frequently cited in connection with the halted trial. The public record does not establish a causal link between that death and CJC-1295 [7], and this site does not assert one — but the discontinuation is part of the compound's status: a GHRH analog whose sponsor-led development ended without an approved product. That history, together with the 2024 PCAC determination and the WADA S2 listing, is the full regulatory picture, and it points consistently in one direction. ## Regulatory and detection summary On the instrument face, the regulatory readout is unambiguous. FDA approval: none. 503A compounding bulks list: not recommended (2024 PCAC) [10]. WADA: prohibited at all times under Section S2. Detection: established by LC-MS/MS and related assays [6]. Each of these is a status fact drawn from the regulatory and analytical record, not an inference. This is the "legal" question this domain reads — not a courtroom verdict, but the actual standing of the compound across the regulatory and anti-doping systems that govern it. The standing is consistent across all of them: unapproved, not compounding-eligible, prohibited in sport, and well-detected. --- An instrument-cluster reading of the CJC-1295 record — the established pharmacokinetics lit in cyan, the unapproved status and missing human data flagged in amber and red, with no clinic behind the console and nothing here prescribed or sold.